Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Gilead Sciences, Inc. trades at $136.1 (market cap $168.35B), while Direxion Daily TSLA Bull 2X Shares trades at $8.05. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| GILD | TSLL | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $23.03 |
52-Week Low | $110.56 | $6.74 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, is trading at $7.975, down 2.86% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF aims to deliver twice Tesla's daily returns, amplifying volatility in a stock known for significant price swings. Recent news highlights its sensitivity to Tesla's performance, with Q2 earnings on July 22, 2026, potentially driving sharp moves.
The outlook for TSLL is highly speculative, tied directly to Tesla's stock volatility, offering leveraged upside but with elevated risk of losses even in rising markets. Investors face risks from daily rebalancing decay, market sentiment shifts, and Tesla-specific developments, requiring caution due to the ETF's non-traditional structure and lack of fundamental company metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
